MESA LABORATORIES INC (MLAB) Stock Fundamental Analysis

NASDAQ:MLAB • US59064R1095

96.57 USD
+1.01 (+1.06%)
At close: Feb 27, 2026
96.57 USD
0 (0%)
After Hours: 2/27/2026, 8:20:25 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to MLAB. MLAB was compared to 57 industry peers in the Life Sciences Tools & Services industry. MLAB scores excellent on profitability, but there are concerns on its financial health. MLAB has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year MLAB was profitable.
  • MLAB had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: MLAB reported negative net income in multiple years.
  • Each year in the past 5 years MLAB had a positive operating cash flow.
MLAB Yearly Net Income VS EBIT VS OCF VS FCFMLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.86%, MLAB is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
  • The Return On Equity of MLAB (2.00%) is better than 71.93% of its industry peers.
  • MLAB's Return On Invested Capital of 3.58% is fine compared to the rest of the industry. MLAB outperforms 68.42% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for MLAB is significantly below the industry average of 11.57%.
  • The 3 year average ROIC (2.10%) for MLAB is below the current ROIC(3.58%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROIC 3.58%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
MLAB Yearly ROA, ROE, ROICMLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • With a decent Profit Margin value of 1.51%, MLAB is doing good in the industry, outperforming 70.18% of the companies in the same industry.
  • MLAB has a better Operating Margin (6.96%) than 66.67% of its industry peers.
  • MLAB's Operating Margin has improved in the last couple of years.
  • MLAB's Gross Margin of 62.40% is amongst the best of the industry. MLAB outperforms 84.21% of its industry peers.
  • MLAB's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
MLAB Yearly Profit, Operating, Gross MarginsMLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so MLAB is destroying value.
  • MLAB has more shares outstanding than it did 1 year ago.
  • MLAB has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, MLAB has an improved debt to assets ratio.
MLAB Yearly Shares OutstandingMLAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M
MLAB Yearly Total Debt VS Total AssetsMLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • Based on the Altman-Z score of 1.55, we must say that MLAB is in the distress zone and has some risk of bankruptcy.
  • MLAB has a Altman-Z score (1.55) which is in line with its industry peers.
  • MLAB has a debt to FCF ratio of 4.41. This is a neutral value as MLAB would need 4.41 years to pay back of all of its debts.
  • MLAB has a Debt to FCF ratio of 4.41. This is in the better half of the industry: MLAB outperforms 71.93% of its industry peers.
  • MLAB has a Debt/Equity ratio of 0.86. This is a neutral value indicating MLAB is somewhat dependend on debt financing.
  • MLAB has a Debt to Equity ratio of 0.86. This is in the lower half of the industry: MLAB underperforms 78.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Altman-Z 1.55
ROIC/WACC0.34
WACC10.47%
MLAB Yearly LT Debt VS Equity VS FCFMLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.94 indicates that MLAB should not have too much problems paying its short term obligations.
  • The Current ratio of MLAB (1.94) is worse than 61.40% of its industry peers.
  • MLAB has a Quick Ratio of 1.45. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.45, MLAB is doing worse than 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.45
MLAB Yearly Current Assets VS Current LiabilitesMLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The earnings per share for MLAB have decreased strongly by -87.40% in the last year.
  • The earnings per share for MLAB have been decreasing by -39.16% on average. This is quite bad
  • MLAB shows a small growth in Revenue. In the last year, the Revenue has grown by 4.12%.
  • MLAB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.41% yearly.
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%

3.2 Future

  • The Earnings Per Share is expected to grow by 247.51% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 4.11% on average over the next years.
EPS Next Y2707.43%
EPS Next 2Y380.33%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MLAB Yearly Revenue VS EstimatesMLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
MLAB Yearly EPS VS EstimatesMLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 150.89, which means the current valuation is very expensive for MLAB.
  • Compared to the rest of the industry, the Price/Earnings ratio of MLAB is on the same level as its industry peers.
  • MLAB's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.07.
  • With a Price/Forward Earnings ratio of 59.80, MLAB can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MLAB is on the same level as its industry peers.
  • MLAB is valuated expensively when we compare the Price/Forward Earnings ratio to 28.05, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 150.89
Fwd PE 59.8
MLAB Price Earnings VS Forward Price EarningsMLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

  • 84.21% of the companies in the same industry are more expensive than MLAB, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of MLAB indicates a rather cheap valuation: MLAB is cheaper than 92.98% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 14.14
EV/EBITDA 15.86
MLAB Per share dataMLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

  • MLAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of MLAB may justify a higher PE ratio.
  • A more expensive valuation may be justified as MLAB's earnings are expected to grow with 247.51% in the coming years.
PEG (NY)0.06
PEG (5Y)N/A
EPS Next 2Y380.33%
EPS Next 3Y247.51%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • MLAB has a yearly dividend return of 0.67%, which is pretty low.
  • MLAB's Dividend Yield is rather good when compared to the industry average which is at 0.10. MLAB pays more dividend than 96.49% of the companies in the same industry.
  • With a Dividend Yield of 0.67, MLAB pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.67%

5.2 History

  • The dividend of MLAB decreases each year by -0.50%.
  • MLAB has been paying a dividend for at least 10 years, so it has a reliable track record.
  • MLAB has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
MLAB Yearly Dividends per shareMLAB Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6

5.3 Sustainability

  • 93.97% of the earnings are spent on dividend by MLAB. This is not a sustainable payout ratio.
DP93.97%
EPS Next 2Y380.33%
EPS Next 3Y247.51%
MLAB Yearly Income VS Free CF VS DividendMLAB Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M -250M
MLAB Dividend Payout.MLAB Dividend Payout, showing the Payout Ratio.MLAB Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

MESA LABORATORIES INC

NASDAQ:MLAB (2/27/2026, 8:20:25 PM)

After market: 96.57 0 (0%)

96.57

+1.01 (+1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03
Earnings (Next)05-26
Inst Owners92.73%
Inst Owner Change-4%
Ins Owners5.44%
Ins Owner Change2.08%
Market Cap533.07M
Revenue(TTM)247.54M
Net Income(TTM)3.73M
Analysts80
Price Target106.59 (10.38%)
Short Float %4.27%
Short Ratio2.31
Dividend
Industry RankSector Rank
Dividend Yield 0.67%
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP93.97%
Div Incr Years0
Div Non Decr Years21
Ex-Date02-27
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)153.03%
Min EPS beat(2)130.33%
Max EPS beat(2)175.74%
EPS beat(4)3
Avg EPS beat(4)44.77%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)420.17%
EPS beat(12)6
Avg EPS beat(12)229.7%
EPS beat(16)8
Avg EPS beat(16)172.52%
Revenue beat(2)1
Avg Revenue beat(2)-0.59%
Min Revenue beat(2)-1.95%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)0.77%
Revenue beat(8)4
Avg Revenue beat(8)0.47%
Revenue beat(12)4
Avg Revenue beat(12)-1.22%
Revenue beat(16)6
Avg Revenue beat(16)-1.01%
PT rev (1m)5.56%
PT rev (3m)10%
EPS NQ rev (1m)-3.77%
EPS NQ rev (3m)-12.82%
EPS NY rev (1m)0%
EPS NY rev (3m)9.16%
Revenue NQ rev (1m)1.07%
Revenue NQ rev (3m)1.07%
Revenue NY rev (1m)1.06%
Revenue NY rev (3m)0.65%
Valuation
Industry RankSector Rank
PE 150.89
Fwd PE 59.8
P/S 2.15
P/FCF 14.14
P/OCF 12.83
P/B 2.86
P/tB N/A
EV/EBITDA 15.86
EPS(TTM)0.64
EY0.66%
EPS(NY)1.61
Fwd EY1.67%
FCF(TTM)6.83
FCFY7.07%
OCF(TTM)7.52
OCFY7.79%
SpS44.84
BVpS33.82
TBVpS-16.71
PEG (NY)0.06
PEG (5Y)N/A
Graham Number22.07
Profitability
Industry RankSector Rank
ROA 0.86%
ROE 2%
ROCE 4.53%
ROIC 3.58%
ROICexc 3.87%
ROICexgc 18.77%
OM 6.96%
PM (TTM) 1.51%
GM 62.4%
FCFM 15.23%
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
ROICexc(3y)2.32%
ROICexc(5y)2.16%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.66%
ROCE(5y)2.18%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y111.19%
ROICexc growth 5Y22.93%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.86
Debt/FCF 4.41
Debt/EBITDA 3.81
Cap/Depr 15.35%
Cap/Sales 1.55%
Interest Coverage 250
Cash Conversion 98.31%
Profit Quality 1009.48%
Current Ratio 1.94
Quick Ratio 1.45
Altman-Z 1.55
F-Score6
WACC10.47%
ROIC/WACC0.34
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
EPS Next Y2707.43%
EPS Next 2Y380.33%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A
EBIT growth 1Y-4.88%
EBIT growth 3Y55.19%
EBIT growth 5Y17.63%
EBIT Next Year193.28%
EBIT Next 3Y47.61%
EBIT Next 5YN/A
FCF growth 1Y-7.43%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y-5.11%
OCF growth 3Y6.07%
OCF growth 5Y11.64%

MESA LABORATORIES INC / MLAB FAQ

Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?

ChartMill assigns a fundamental rating of 5 / 10 to MLAB.


What is the valuation status of MESA LABORATORIES INC (MLAB) stock?

ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.


How profitable is MESA LABORATORIES INC (MLAB) stock?

MESA LABORATORIES INC (MLAB) has a profitability rating of 7 / 10.


What is the financial health of MESA LABORATORIES INC (MLAB) stock?

The financial health rating of MESA LABORATORIES INC (MLAB) is 3 / 10.


Can you provide the expected EPS growth for MLAB stock?

The Earnings per Share (EPS) of MESA LABORATORIES INC (MLAB) is expected to grow by 2707.43% in the next year.